EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression

Changchun Long, Shiqi Wang, Yiyong Wang iD

PLOS One · 27.07.2026 · 21 (7) · e0353621

DOI: 10.1371/journal.pone.0353621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 27.07.2026. Verfasst von Changchun Long und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shanghai Baoshan Luodian Hospital, Baoshan, Shanghai, China. Hauptthemen laut MEDLINE: Cisplatin, Uterine Cervical Neoplasms, Drug Resistance, Neoplasm, Osteopontin. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy resistance is a major treatment issue for cervical cancer (CC), contributing to high morbidity and mortality. This study identifies key molecular drivers of CC progression and cisplatin (DDP) resistance, focusing on secreted phosphoprotein 1 (SPP1).

Methods

Differentially expressed genes (DEGs) were identified from TCGA-CC and GSE46857 datasets. Protein-protein interaction network analysis and topological ranking determined candidate genes. SPP1 expression was evaluated in CC cell lines using qPCR and Western blotting. Cisplatin-resistant CC cells were used to examine SPP1’s role in drug resistance. Functional assays assessed cell proliferation, apoptosis, migration, and invasion.

Results

Bioinformatics analysis identified SPP1 as a hub gene upregulated in CC. SPP1 expression was higher in CC and DDP-resistant cells. Silencing SPP1 inhibited cell growth and enhanced apoptosis, while overexpression had the opposite effects. Silencing SPP1 enhanced DDP sensitivity, while overexpression reduced DDP cytotoxicity. Mechanistically, SPP1 positively correlated with KRAS expression, and KRAS modulation partially reversed SPP1’s effects on DDP resistance.

Conclusion

SPP1 is upregulated in CC and DDP-resistant cells, promoting tumor progression and chemoresistance via KRAS. Targeting the SPP1-KRAS axis may help overcome chemotherapy resistance in CC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinUterine Cervical NeoplasmsDrug Resistance, NeoplasmOsteopontinProto-Oncogene Proteins p21(ras)HumansFemaleGene Expression Regulation, NeoplasticCell Line, TumorApoptosisCell ProliferationAntineoplastic AgentsCell Movement

Substanzen

CisplatinOsteopontinProto-Oncogene Proteins p21(ras)KRAS protein, humanSPP1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shanghai Baoshan Luodian Hospital, Baoshan, Shanghai, China.

ORCID-Profile: Yiyong Wang

Zitieren

APA

Long, C., Wang, S., & Wang, Y. (2026). SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression. PLOS One, 21(7), e0353621. https://doi.org/10.1371/journal.pone.0353621

Vancouver

Long C, Wang S, Wang Y. SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression. PLOS One. 2026;21(7):e0353621. doi:10.1371/journal.pone.0353621

BibTeX
@article{Long2026,
  author = {Long, Changchun and Wang, Shiqi and Wang, Yiyong},
  title = {SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0353621},
  doi = {10.1371/journal.pone.0353621}
}
Kostenlos starten →